Clinical trial
Phase II Study of IL-11 (Neumega) in Von Willebrand Disease
NCT00151125 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00151125 |
|---|---|
| Title | Phase II Study of IL-11 (Neumega) in Von Willebrand Disease |
| Official title | Phase II Comparison Study of Hemostatic Efficacy of Escalating Doses of Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry University of North Carolina |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Von Willebrand Disease |
| Intervention type | Drug |
| Interventions | recombinant interleukin-11 |
| Enrollment | 12 |
| Start date | Jul 1, 2004 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 8, 2005 |
| Last update posted | May 17, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: